Biotechnology

One year after its US launch, Pictor Holdings is gaining traction with a platform that makes complex disease testing fast, cheap, and accessible. But can its unique business model truly scale?

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

A new study reveals molecular and AI-imaging tests provide distinct clues for Parkinson's, championing a dual-biomarker approach for earlier, more accurate diagnosis.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

Origin Agritech's gene-editing breakthrough allows corn to mature faster without sacrificing yield, a holy grail for breeders and a boon for global food security.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

A Japanese firm has achieved a breakthrough in manufacturing ultra-smooth capillary tubes, a tiny component set to unlock major advances in medicine and tech.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

As Nanobiotix joins Europe's tech elite, its nanotech cancer therapy gains a powerful spotlight, signaling a new era for physics-based medicine.

Early data shows a first-in-class oral drug helps immunotherapy work again in resistant tumors, offering a glimpse of hope where options are running out.

With revenues soaring 50%, program manager Primecore is launching into semiconductors and data centers, betting its veteran team can tame the world's most complex projects.

An innovator in single-molecule imaging is teaming up with a multiplex giant. This collaboration could redefine diagnostic sensitivity and market dynamics.

China's CHANDO Group is turning Himalayan biodiversity and advanced R&D into a potent business strategy, setting a new benchmark for sustainable growth in beauty.

Rakovina Therapeutics reports a dramatic financial recovery, slashing costs while boosting AI-driven R&D, positioning its promising cancer pipeline for growth.

As CEO Richard Francis prepares for a key address, Teva's 'Pivot to Growth' is under the microscope. Can innovation truly outpace its generics legacy?